Details

Autor(en) / Beteiligte

• Sharif-Askari, Fatemeh Saheb
• Sharif-Askari, Narjes Saheb
• Hafezi, Shirin
• Mdkhana, Bushra
• Alsayed, Hawra Ali Hussain
• Ansari, Abdul Wahid
• Mahboub, Bassam
• Zakeri, Adel M
• Temsah, Mohamad-Hani
• Zahir, Walid
• Hamid, Qutayba
• Halwani, Rabih
• Shankar, Esaki M.

Titel

Interleukin-17, a salivary biomarker for COVID-19 severity

Ist Teil von

• PloS one, 2022-09, Vol.17 (9), p.e0274841-e0274841

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• T-helper 17 cell-mediated response and their effector IL-17 cytokine induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a major cause of COVID-19 disease severity and death. Therefore, the study aimed to determine if IL-17 level in saliva mirrors its circulatory level and hence can be used as a non-invasive biomarker for disease severity. Interleukin-17 (IL-17) level was evaluated by ELISA in saliva and blood of 201 adult COVID-19 patients with different levels of severity. The IL-17 saliva level was also associated with COVID-19 disease severity, and need for mechanical ventilation and/or death within 29 days after admission of severe COVID-19 patients. We found that IL-17 level in saliva of COVID-19 patients reflected its circulatory level. High IL-17 level in saliva was associated with COVID-19 severity (P<0.001), need for mechanical ventilation (P = 0.002), and/or death by 29 days (P = 0.002), after adjusting for patients' demographics, comorbidity, and COVID-19 serum severity markers such as D-Dimer, C-reactive protein, and ferritin. We propose that saliva IL-17 level could be used as a biomarker to identify patients at risk of developing severe COVID-19.